- Clinical Trials
Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials
Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.
A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.
Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.
Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.